Best UVB Lamps for Vitiligo: How to Choose the Right One for Home Use

You notice a pale patch — on your wrist, around your lips, the back of your hand. You look it up. The word vitiligo appears, and with it comes a flood of creams, supplements, forum debates, and half-answers. But deeper in that research, something different keeps surfacing: UVB light therapy. Narrowband UVB phototherapy. Clinical evidence. Actual results. If you have reached the point where you are wondering whether a UVB lamp for vitiligo might genuinely help, this guide is for you — a clear, science-based resource to help you understand what works, what to look for, and what to realistically expect.
One important thing to understand from the outset: narrowband UVB light treatment is not a cure for vitiligo. It manages and controls the condition — achieving repigmentation that, for many patients, is durable and long-lasting, but that can relapse in some patients if no maintenance treatment is continued after the active course ends. This is not a reason to be discouraged — it is a reason to think carefully about your device choice. A home device you own is available the moment a patch returns or spreads, without waiting lists, without clinic appointments, and without starting from scratch. For a lifelong condition, that access is not a convenience. It is part of the vitiligo treatment strategy.

What Is UVB Light Therapy and How Does It Help Vitiligo?

Vitiligo is not a surface-level skin problem. It is a chronic autoimmune condition in which the immune system's own T cells identify and destroy melanocytes — the cells responsible for producing skin pigment. What shows up as white patches on the skin is the aftermath of that immune attack: areas where the pigment-producing machinery has been switched off.
Narrowband UVB phototherapy works on two levels simultaneously. At the therapeutic wavelength of 311 nm, UVB light calms the autoimmune response that has been destroying melanocytes, and it stimulates dormant melanocyte stem cells — particularly those sheltering in hair follicles at the edges of patches — to migrate back into depigmented skin. It is this dual action that has made NB-UVB the standard of care for vitiligo globally, not merely one option among many.
In clinical practice, this is reflected clearly in treatment guidelines. The Vitiligo Working Group Phototherapy Committee — drawing on the expertise of specialists from around the world — created a unified set of recommendations for the use of NB-UVB in vitiligo, positioning it as first-line phototherapy for three specific indications: extensive disease, rapidly spreading disease, and patients who have not responded adequately to topical therapies alone. Critically, those same guidelines explicitly include home phototherapy as a valid and recommended treatment pathway within this framework — not as a compromise on clinical standards, but as a patient-centred route to the same evidence-backed therapy (Smith et al., Clinical, Cosmetic and Investigational Dermatology, 2019).

Why 311 nm — and not just any UV light?

Ultraviolet light covers a broad spectrum, but not all of it is equally useful — or equally safe. The 311 nm window captures all of the therapeutic benefit of UV exposure whilst cutting out the wavelengths responsible for burning, premature skin ageing, and unnecessary cellular stress. This matters enormously in a condition like vitiligo, where UVB light treatment runs for months, not days.
Broadband UVB covers a far wider range of wavelengths. It was used in earlier phototherapy protocols and remains in some older devices, but it delivers a less favourable benefit-to-risk ratio: shorter safe exposure windows, a higher risk of burning, and weaker therapeutic precision. Sunbeds and tanning lamps are a different matter entirely — they emit primarily UVA, which has a different mechanism, a much weaker repigmenting effect in vitiligo, and a well-established association with long-term skin damage. They are not a substitute for narrowband UVB light.

What the clinical evidence actually shows

The evidence base for NB-UVB in vitiligo is substantial. A 2022 systematic review and meta-analysis published in Dermatological Reviews (Wang et al.) pooled data from multiple prospective NB-UVB trials and found that at least 25% repigmentation was achieved in 74.2% of patients after six months and 75.0% after twelve months. At least 50% repigmentation was observed in 37.4% of patients at six months, rising to 56.8% at twelve months. At least 75% repigmentation was seen in 19.2% of patients at six months and 35.7% at twelve months.
Two things stand out in those numbers. First, outcomes improve meaningfully with time — patients who reach twelve months of consistent treatment do significantly better than those who stop at six. Second, and directly relevant to anyone considering a home device: a 2026 systematic review and meta-analysis published in PMC (Tien Guan et al.) analysed 18 studies covering 1,341 vitiligo patients and found that home-based UVB was not inferior to in-office UVB at achieving either more than 50% or more than 75% repigmentation. Home-based patients also showed a 14% lower rate of treatment discontinuation — meaning they were more likely to complete their course than those attending a clinic.
The implication is important: access and consistency are what drive results. A UVB lamp for vitiligo that you can use three times a week at home, on your own schedule, will outperform a clinic appointment you can only attend once a week and frequently have to reschedule.

Is UVB Therapy Safe and Are There Side Effects?

This is the question most people ask second — right after "does it work?" — and it deserves a straight answer rather than a wall of disclaimers.
NB-UVB phototherapy has one of the most well-established safety profiles of any treatment used in dermatology. It has been studied continuously for more than two decades, used in clinical settings across the world, and validated as safe for populations that many treatments exclude: children, pregnant women, and patients on long-term management programmes. The 2019 Vitiligo Working Group consensus published in the Journal of the American Academy of Dermatology explicitly notes its favourable safety record as one of the key reasons NB-UVB treatment holds first-line status in clinical practice.
That does not mean it is without any side effects. It means the side effects are well understood, mostly mild, and manageable — which is a very different thing.

What you will commonly experience

The most frequently reported side effects of NB-UVB phototherapy are temporary redness and itching of the treated skin. Erythema — the faint pinkness that appears within a few hours of a session — typically resolves on its own within 24 hours. Mild itching, particularly in the early weeks of treatment, is equally common and equally transient. In some cases a gentle sensation of warmth accompanies both. These responses are not signs that something is wrong. They are, in controlled measure, expected — a faint pink response with mild itching after treatment indicates the dose has reached the therapeutic threshold.
The distinction worth understanding is between minimal erythema — the faint response that signals effective dosing — and significant burning, which indicates overexposure. The former is the optimal response. The latter is avoidable, and is most commonly the result of dosing errors: either starting too high, or failing to account for the skin's increasing sensitivity during a course of treatment. This is precisely why dose precision matters so much, and why a device with a built-in dosimeter — measuring dose in mJ/cm² in real time rather than relying on a timer — offers a meaningful safety advantage over devices that simply count seconds.

What about long-term skin safety?

The concern patients most often raise is skin cancer risk. It is a reasonable question, and the evidence is reassuring. A 2022 review published in Dermatological Reviews (Wang et al.) notes that unlike PUVA therapy — which uses a photosensitising agent alongside UVA light and carries a documented elevated risk of squamous cell carcinoma with long-term use — NB-UVB has not been shown to carry a clinically significant carcinogenic risk at therapeutic doses. By excluding the broader UV spectrum, narrowband UVB light significantly reduces cumulative DNA damage compared to broadband UV exposure. It is worth adding context: uncontrolled sun exposure accumulated over a lifetime carries far greater cumulative UV risk than a structured UVB phototherapy course administered at measured, therapeutic doses.

Who should not use NB-UVB without medical guidance

Phototherapy is not universally appropriate, and responsible use means knowing the contraindications. The following groups should consult a dermatologist before beginning any home phototherapy programme:

• Patients taking photosensitising medications — including certain antibiotics, diuretics, and psychiatric medications — which can dramatically lower the skin's threshold for UV damage

• Those with a personal or family history of skin cancer, or a diagnosis of xeroderma pigmentosum or lupus erythematosus

• Patients with a history of photosensitivity disorders

• Individuals who have undergone immunosuppressive therapy

This is not an exhaustive list — and it is not a reason to be discouraged. For the majority of people with vitiligo, NB-UVB is not only safe, it is the most effective treatment available with the strongest evidence base. The precautions exist to protect the minority for whom it requires additional oversight, not to suggest that phototherapy is inherently risky.

Medical guidance and certified devices are not optional extras

This point deserves emphasis. Home phototherapy is safe and well-evidenced — but that safety record is built on studies conducted with medical-grade, certified devices, under protocols developed and supervised by dermatologists. The risk in home treatment does not come from the therapy itself. It comes from using uncertified equipment with no dosing controls, no clinical documentation, and no established safety standards — and assuming the results will be the same.
Before starting any home phototherapy programme, discuss it with your dermatologist. They can confirm NB-UVB light therapy is appropriate for your specific situation, establish your starting dose based on your skin phototype, and monitor your progress over time. And when choosing a device, look specifically for CE MDR Class IIa medical device certification in Europe — the regulatory standard that confirms a device has been evaluated not just as a consumer product, but as a clinical therapeutic tool. The difference matters.

Types of UVB Lamps for Home Treatment

Not all home phototherapy devices are built the same way — and the differences between them are not merely cosmetic. The type of device you choose will determine how precisely you can dose your treatment, how consistently you can maintain it, and ultimately how likely you are to see results. Understanding the landscape before you buy is time well spent.
Home UVB devices for vitiligo fall into three broad categories based on form factor, and two fundamentally different categories based on the light source technology inside them. Both distinctions matter.

Form factor: matching the device to your vitiligo

The first question is a practical one — how much skin do you need to treat, and where?
Handheld devices are the most portable and accessible entry point into home phototherapy. Compact enough to fit in the palm, they are designed to treat localised areas — a patch on the wrist, around the lips, on the back of a hand, or along a hairline. They are the format most extensively studied in home-based clinical trials, including the HI-Light feasibility trial led by Eleftheriadou et al., published in Trials (2014), which demonstrated that handheld NB-UVB devices are both safe and effective for home treatment of focal vitiligo. Their limitation is coverage: if your vitiligo affects multiple body areas, treating each patch individually takes time, and time per session is a direct predictor of long-term adherence.
Panel devices offer wider treatment coverage and are better suited for vitiligo affecting the torso, limbs, or multiple areas simultaneously. A single repositioning rather than patch-by-patch treatment makes sessions faster and more manageable. The trade-off is size and cost — panel units sit at a higher price point and are less portable — but for anyone with moderate involvement across several body regions, the efficiency gains translate directly into better consistency over the months that treatment requires.
Full-body cabinets — the standing units familiar from dermatology clinics — are also available for home use, and represent the most efficient delivery format for extensive vitiligo affecting large body surface areas. They are, however, a significant investment in both cost and space, and are rarely the right starting point for most patients. For truly extensive, full-body vitiligo involvement, a home device of any kind may not be sufficient — clinic-based treatment or a dermatologist-supervised programme is the more appropriate path.
The practical guide is straightforward: localised vitiligo on several areas suits a quality handheld UVB lamp. Multiple body regions benefit from a panel unit. Extensive involvement across large surface areas warrants a dermatologist conversation before any device purchase.

Light source technology: the difference that most buyers overlook

Form factor is visible and easy to compare. Light source technology is less obvious — but it determines the precision, consistency, and longevity of every NB-UVB treatment you perform.
Most home UVB phototherapy devices use fluorescent lamp technology — well-studied and clinically familiar, but with a fundamental limitation: output degrades over time. As a bulb ages, its output intensity decreases — meaning that a session timed for the same number of seconds in month one and month twelve will deliver a meaningfully different UV dose. On a timer-based device, the patient has no way of knowing this is happening. The dose they believe they are receiving and the dose they are actually receiving quietly diverge.
A dosimetry study by Rogers et al. published in the British Journal of Dermatology (2021), conducted within the HI-Light Vitiligo Trial, measured this directly: handheld fluorescent devices lost a mean 34% of their output over a 9-month treatment course. For a condition requiring months of consistent, correctly dosed treatment, that is a significant and invisible problem.
LED-based devices operating at 311 nm take a different approach entirely. LEDs degrade far more slowly than fluorescent sources, maintaining consistent output across thousands of treatment hours — which is precisely why devices such as UV Tactus, a CE MDR Class IIa certified LED-based device operating at precisely 311 nm, are designed around this technology for long-term home use. A further advantage specific to LED architecture is zone control: the treatment surface can be divided into independently controllable zones, so only the skin that actually needs treating is exposed. UV Tactus offers four individually controllable zones in a single handheld unit — a meaningful practical advantage for vitiligo patients managing several small patches surrounded by healthy skin that tans normally with UV exposure. Activating only the relevant zones keeps treatment precisely targeted and directly reduces contrast between treated and untreated areas.

What to Look for When Choosing a UVB Lamp

Knowing the device categories is one thing. Knowing what separates a reliable medical device from a product that merely looks the part is another. By the time you are comparing specific devices, these are the criteria that should be doing the work.
CE Class IIa medical device certification — non-negotiable in Europe
In the European market, a CE medical device certification is not a quality badge. It is a regulatory requirement — and the class of certification tells you precisely how rigorously the device has been evaluated. Class IIa covers medium-risk medical devices and requires independent assessment by a notified body. A device carrying CE MDR Class IIa certification has been evaluated for clinical safety, performance, and manufacturing quality to the same standard as equipment used in dermatology clinics.
A CE mark alone — without the class designation and notified body number — is not sufficient. Consumer electronics can carry a CE mark. What you are looking for on a UVB lamp is the full regulatory designation: CE MDR Class IIa, with an identifiable notified body. A notified body is an organisation officially designated by an EU member state to assess medical devices — you can identify one by its four-digit identification number, which must appear on the product label alongside the CE mark (for example, CE 0197 identifies TÜV Rheinland). If that number is absent, the device has not undergone independent third-party assessment. If that information is not clearly stated in the product documentation, the regulatory status of the device is uncertain. In the UK, look additionally for MHRA listing, which confirms the device meets the standards required for the British market.

Verified wavelength at 311 nm

This should be stated explicitly in the product's technical specifications — not described as narrowband UVB without further detail, and certainly not referred to generically as UV light. The 311 nm range is specific and non-negotiable for vitiligo treatment. A device that cannot or does not specify its emission wavelength with precision does not meet the standard required for this indication.

Integrated dosimeter versus timer: why it matters for vitiligo specifically

The majority of home phototherapy devices are timer-based — meaning they measure treatment duration in seconds rather than the actual UV energy delivered to the skin. As the lamp degrades over time, the same number of seconds produces progressively less therapeutic output, with no way for the patient to detect the difference. As discussed in the previous section, this is not a minor technical detail: over a 9-month course, the impact on dose consistency is clinically significant.
An integrated dosimeter solves this directly. Rather than counting seconds, it measures the actual UV dose delivered to the skin in mJ/cm² in real time and stops the session automatically when the correct dose is reached — regardless of how the device is performing on any given day. For vitiligo, where treatment routinely extends to twelve months or longer, this is the single most important technical specification after wavelength. The question of whether a device measures what it delivers is not a minor specification. It is the foundation of safe, effective, and reproducible home phototherapy.

Treatment area and zone flexibility — particularly relevant for vitiligo

This is a specification that matters more for vitiligo than for almost any other photoresponsive condition, and it is one that is easy to overlook when comparing devices on paper.
Vitiligo patches vary considerably in size and location — and critically, they are often surrounded by healthy, normally pigmented skin. During the early months of treatment, when repigmentation is beginning but not yet visible, the surrounding skin continues to tan normally with UV exposure. The greater the area of healthy skin exposed unnecessarily during each session, the more pronounced the contrast between treated and untreated areas can temporarily become. A device that allows you to treat a smaller, precisely defined area — shielding the adjacent healthy skin from UVB exposure — reduces this contrast effect and keeps UVB light treatment focussed exactly where it needs to be.
Look for devices that include silicone applicators or shields in different sizes, and that offer zone control over the treatment surface. The ability to adapt the treatment window to the actual size of a patch — rather than always exposing the maximum available area — is a meaningful clinical advantage for vitiligo specifically.

Ease of use and built-in safety features

A UVB lamp you will use three times a week for months needs to be genuinely easy to operate. Look for a fully digital interface with clear controls, an LCD display, and key actions that require confirmation before proceeding. Automatic shutoff when the correct dose is reached is not merely convenient — for a device emitting therapeutic UV light, it is a safety feature. Forgetting to manually stop a session is a realistic scenario during a long treatment course, and a device that handles this automatically removes one more point of human error.
Hands-free accessories — such as adjustable straps for longer sessions on the limbs or torso — also make a practical difference to daily usability. A device that can be secured in place lets you treat comfortably without needing to hold it in position for the entire session.

Companion app and protocol guidance

Home phototherapy requires a structured protocol — a starting dose, a dose escalation schedule, and a consistent session frequency. Adherence to that protocol has a direct impact on treatment outcomes: missed sessions, incorrect dose escalation, and inconsistent scheduling do not merely slow progress — they undermine the cumulative biological process that repigmentation depends on. Adherence over months is therefore one of the most clinically significant limitations of home-based treatment, and clinical evidence points to structured patient training and protocol reminders as meaningful ways to address it. A newer approach — still far from standard across the market — accompanies the device with a dedicated companion app that guides the patient through the full treatment protocol, calculates the correct dose per body area and session, sends reminders, and allows progress tracking. The app brings the structure of a clinically supervised programme into an independent home setting — removing the guesswork and supporting the consistency that drives results. UV Tactus is among the devices that have adopted this approach, treating protocol support as a core part of the treatment experience rather than an afterthought.

Cost and long-term value: what the price range actually reflects

Quality home phototherapy devices range broadly in price — from around EUR 500 at the lower end to EUR 2,000 for premium medical-grade units. That range reflects real differences in technology, certification, dosing precision, build quality, and support. A device at the lower end of that range may be a fluorescent UVB lamp in a handheld casing with a basic timer and no dosimetry. A device at the upper end is likely LED-based, dose-controlled, certified to medical device standards, supported by a companion app, and built to perform thousands of treatments over its lifetime.
The frame that matters is not "how little can I spend?" but "what is the cost per treatment over the device's usable life, and what is the cost of getting it wrong?" For a treatment course that extends across months or years — and for a condition that can relapse and require retreatment — a device that delivers imprecise dosing, requires frequent bulb replacement, or lacks clinical certification is not a bargain. It is a liability.

"For a treatment that runs across months, the question is not which device is cheapest — it is which device will still be delivering the correct dose in session one hundred that it delivered in session one."

A new generation of home phototherapy devices has been engineered to directly address the limitations that have historically held home treatment back — lamp degradation, imprecise dosing, lack of protocol structure, and insufficient targeting precision — taking the clinical evidence base for NB-UVB and building the answers into the device itself. Certified to medical device standards, built on LED technology for output stability, equipped with real-time dosimetry, zone-controllable for precision targeting, and accompanied by a companion app that manages the full treatment protocol — from starting dose to session reminders to progress tracking. UV Tactus is one such device — developed by SCI Health in Lithuania and trusted at Vilnius University Hospital Santaros Clinics, it was designed from the ground up for patients who want clinical-standard phototherapy at home, without accepting the compromises that earlier home devices required.
When evaluating any device, look for a minimum 24-month manufacturer's guarantee, clarity on LED or lamp lifespan, and a manufacturer that offers pre-purchase consultation and active onboarding — signals that they are invested in your results, not just in completing a transaction.

How to Use a Home UVB Lamp Safely

Understanding that narrowband UVB phototherapy works is one thing. Knowing how to actually use it correctly at home — session by session, week by week — is what determines whether those clinical results translate into your results. The protocol is not complicated, but the details matter.
The standard NB UVB treatment protocol for vitiligo is three sessions per week on alternate days. Rest days matter: they allow the biological processes of repair and early melanin synthesis to occur without interruption. The specific dosing protocol — starting dose, escalation schedule, and session duration — will be set either by your dermatologist or by the device's own protocol guidance, and should be followed precisely (Khanna & Khandpur, Indian Dermatology Online Journal, 2019).
Each session should be carried out following the device's instructions for use. Keep the treatment area clean before a session — avoid perfumes, retinoids, alpha-hydroxy acids, or any photosensitising products on the skin. After a session, keep it gentle, avoid harsh products on the treated area, and be mindful of additional sun exposure to treated skin on the same day.
Resist the temptation to treat more often or at higher doses to speed things up. Consistency over months is what delivers results — not intensity at any single session.

What Results to Expect from UVB Treatment

This is the section most people skip to first — and understandably so. When you are living with vitiligo, the practical question is not whether the science is elegant. It is: will I actually see results, and how long will it take?
The honest answer is that narrowband UVB phototherapy produces meaningful repigmentation in the majority of patients who complete a proper treatment course — but vitiligo is not a condition that responds to impatience, and setting realistic expectations from the outset is part of what makes treatment succeed.

What the numbers actually say

The most comprehensive picture comes from a systematic review and meta-analysis by Bae et al., published in JAMA Dermatology (2017), which analysed 35 prospective studies covering 1,428 patients. At six months of consistent treatment, 74.2% of patients achieved at least 25% repigmentation — rising to 75.0% at twelve months. At least 50% repigmentation rose from 37.4% to 56.8%, and at least 75% repigmentation climbed from 19.2% to 35.7% over the same period.
The patients who reach twelve months of consistent NB-UVB treatment achieve results almost double those of patients who stop at six. That single fact is the strongest argument for choosing a home device over clinic-based treatment — because completing twelve months of three-sessions-per-week UVB phototherapy in a clinical setting is, for most people, logistically impossible.

Where on the body results appear first

Not all areas of the skin respond at the same rate, and understanding this prevents a common source of discouragement. Bae et al. showed that the face and neck respond most strongly: 82% of patients treating these areas achieved at least 25% repigmentation — the highest regional response rate in the study. The trunk followed at 81.7%, with the arms and legs at 79.0%. The hands and feet are the least responsive areas, with only around 11% of patients achieving meaningful repigmentation, reflecting the relative scarcity of melanocyte stem cells in acral skin.
If your vitiligo affects the hands or feet primarily, this does not mean treatment is futile — it means expectations need to be calibrated accordingly, and that your dermatologist's guidance on treatment prioritisation is worth seeking.

Does it matter how long you have had vitiligo?

Yes — and the evidence is direct. A clinical trial by Hallaji et al., published in Photodermatology, Photoimmunology & Photomedicine (2012), classified patients as having either recent vitiligo — defined as a disease duration of four years or less — or long-standing vitiligo — defined as more than four years. Higher grades of repigmentation were significantly more prevalent in the recent vitiligo group (P = 0.023). That said, the mean overall response across all patients, including those with long-standing disease, was still 51.94% — meaning older patches can and do respond to NB-UVB treatment. The message is not that long-standing vitiligo cannot be treated, but that starting earlier gives the best chance of a stronger response. For anyone currently weighing whether to begin treatment, that is a clinically meaningful reason not to wait.

How many sessions before you can assess whether treatment is working

This is a question that matters enormously for motivation. Bae et al. are explicit: at least six months of treatment — roughly 72 sessions at three sessions per week — is required to determine responsiveness to NB-UVB phototherapy. Three months is not sufficient to discriminate non-responders from late responders, as 37.9% of patients who did not achieve a mild response at three months went on to respond with continued treatment. Stopping early because results are not yet visible is one of the most common — and most avoidable — reasons treatment fails.
The onset of repigmentation is gradual and easy to miss in its earliest stages. The first visible sign is typically small pigmented dots appearing within or at the margins of a depigmented patch — perifollicular repigmentation from melanocyte stem cells in hair follicles. These dots gradually enlarge and coalesce over subsequent weeks and months. They are not the finish line; they are the starting gun.

How durable are the results?

A retrospective study published in PMC (Mousa et al., 2025) followed 176 vitiligo patients treated with narrowband UVB light for up to 19 years. Of those who achieved clinically significant repigmentation, 95% maintained their results for at least six months after stopping treatment — and 59% were still holding colour more than six years later. These are meaningful evidence that the repigmentation achieved through a completed NB-UVB treatment course is not superficial or short-lived. For patients who do experience recurrence, having a home UVB lamp available means retreatment can begin promptly — without waiting lists, and without starting the learning curve again.

Setting realistic expectations

The timeline for meaningful, visible repigmentation in vitiligo is measured in months, not weeks. Optimal results develop over six to twelve months of consistent UVB phototherapy — and the evidence is clear that longer courses produce substantially better outcomes. This is not a reason for discouragement. It is the reality of a biological process that cannot be rushed — and one that, with the right device, the right protocol, and the consistency that home treatment makes possible, delivers results in the majority of patients who see it through.

Final Tips and When to Seek Professional Help

NB-UVB phototherapy is one of the most evidence-backed and well-tolerated treatments available for vitiligo — meaningful repigmentation is an achievable outcome for the majority of patients who commit to a proper course. Treatment takes time: results build over months, and at least six months is needed before drawing any conclusions about response. Before starting, a brief dermatologist consultation is always advisable to ensure home treatment is appropriate for your specific situation. Follow the protocol precisely: three sessions per week, correct dose escalation, clean skin beforehand, emollient and SPF after. Track your progress with photographs — repigmentation is too gradual to perceive day to day. And start sooner rather than later — the evidence shows that patches of less than four years respond more strongly than long-standing disease.
Stop treatment and consult your dermatologist if you experience significant burning or blistering that does not resolve within 24–48 hours, new or spreading depigmentation during a course, any new or changing skin lesion near a treated area, or if you start a new medication with potential photosensitivity effects.
Vitiligo is a chronic condition — NB-UVB is not a single course with a finish line but a long-term management tool. Results can last for years after a completed course, and when patches do return, the ability to begin retreatment immediately makes all the difference. When choosing a device, it is worth looking at the new generation of home phototherapy devices that have been specifically engineered to address the limitations of earlier home treatment — precision dosing, output stability, zone control, and protocol support built in. UV Tactus is one of them. Choose wisely — for a condition that will be part of your life for years, it matters.

Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. Always consult a qualified dermatologist before beginning any phototherapy programme, particularly if you have underlying health conditions or are taking medication. UV Tactus is a CE MDR Class IIa certified medical device. Results vary between individuals.